雄激素受体与乳腺癌内分泌耐药的研究进展
《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]
- 期数:
- 2021年03期
- 页码:
- 524-527
- 栏目:
- 综述
- 出版日期:
- 2020-12-31
文章信息/Info
- Title:
- Research progress of androgen receptor and endocrine resistance in breast cancer
- Author(s):
- WANG Jiaming; LI Ningning; TANG Yi; SU Rong
- Department of Breast Sugery，the Third Affiliated Hospital of Guangzhou Medical University，Guangdong Guangzhou 510150，China.
- Keywords:
- androgen receptor; breast cancer; endocrine resistance; prognosis
- 分类号:
- R737.9
- DOI:
- DOI：10.3969/j.issn.1672-4992.2021.03.037
- 文献标识码:
- A
- 摘要:
- 乳腺癌是女性最常见的恶性肿瘤。其中雌激素受体（ER）阳性乳腺癌对内分泌治疗敏感，通过规范的内分泌治疗，患者复发及死亡风险显著降低。但是，内分泌耐药的出现成为临床治疗中最大的障碍。雄激素受体（AR）在ER阳性乳腺癌中广泛表达，与ER之间存在串扰，影响乳腺癌发展、内分泌耐药及预后。本文就AR在ER阳性乳腺癌中的作用机制、预后及内分泌治疗影响，尤其是内分泌耐药的相关研究进展进行综述。
- Abstract:
- Breast cancer is the most common malignancies in females.Estrogen receptor（ER） positive breast cancer is sensitive to endocrine therapy，and the risk of recurrence and death is significantly reduced by standardized endocrine therapy.However，endocrine resistance has become the biggest obstacle in clinical treatment.Androgen receptor（AR）is widely expressed in ER-positive breast cancer，and there is the crosstalk between AR and ER，which affects cancer development，endocrine resistance and prognosis.This article reviews the role of AR in mechanism，prognosis and endocrine therapy，especially endocrine resistance in ER-positive breast cancer.
参考文献/References
[1]BRAY F，FERLAY J，SOERJOMATARAM I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68(6)：394-424.
[2]EBCTCG EBCT.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival：An overview of the randomised trials［J］.Lancet，2005，365(9472)：1687-1717.
[3]SZOSTAKOWSKA M，TREBINSKA-STRYJEWSKA A，GRZYBOWSKA EA，et al.Resistance to endocrine therapy in breast cancer：Molecular mechanisms and future goals［J］.Breast Cancer Research and Treatment，2019，173(3)：489-497.
[4]HAQUE MM，DESAI KV.Pathways to endocrine therapy resistance in breast cancer［J］.Frontiers in Endocrinology，2019，10(1)：573-580.
[5]LI W，O' SHAUGHNESSY J，HAYES D，et al.Biomarker associations with efficacy of abiraterone acetate and exemestane in postmenopausal patients with estrogen receptor-positive metastatic breast cancer［J］.Clinical Cancer Research，2016，22(24)：6002-6009.
[6]HICKEY TE，IRVINE CM，DVINGE H，et al.Expression of androgen receptor splice variants in clinical breast cancers［J］.Oncotarget，2015，6(42)：44728-44744.
[7]CIMINO-MATHEWS A，HICKS JL，ILLEI PB，et al.Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy［J］.Hum Pathol，2012，43(7)：1003-1011.
[8]PONNUSAMY S，ASEMOTA S，SCHWARTZBERG LS，et al.Androgen receptor is a non-canonical inhibitor of wild-type and mutant estrogen receptors in hormone receptor-positive breast cancers［J］.iScience，2019，21：341-358.
[9]HE L，DU Z，XIONG X，et al.Targeting androgen receptor in treating HER2 positive breast cancer［J］.Sci Rep，2017，7(1)：14584-14593.
[10]GUCALP A，TOLANEY S，ISAKOFF SJ，et al.Phase II trial of bicalutamide in patients with androgen receptor-positive，estrogen receptor-negative metastatic breast cancer［J］.Clin Cancer Res，2013，19(19)：5505-5512.
[11]MCNAMARA KM，MOORE NL，HICKEY TE，et al.Complexities of androgen receptor signalling in breast cancer［J］.Endocr Relat Cancer，2014，21(4)：161-181.
[12]SULTANA A，IDRESS R，NAQVI ZA，et al.Expression of the androgen receptor，pAkt，and pPTEN in breast cancer and their potential in prognostication［J］.Transl Oncol，2014，4(4)：355-362.
[13]DE AMICIS F，THIRUGNANSAMPANTHAN J，CUI Y，et al.Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells［J］.Breast Cancer Research and Treatment，2010，121(1)：1-11.
[14]SALVI S，BONAFE M，BRAVACCINI S.Androgen receptor in breast cancer：A wolf in sheep's clothing? A lesson from prostate cancer［J］.Semin Cancer Biol，2020，60：132-137.
[15]CLAESSENS F，DENAYER S，VAN TILBORGH N，et al.Diverse roles of androgen receptor(AR) domains in AR-mediated signaling［J］.Nuclear Receptor Signaling，2018，6(1)：6008-6020.
[16]NARAYANAN R，DALTON JT.Androgen receptor：A complex therapeutic target for breast cancer［J］.Cancers(Basel)，2016，8(12)：108-124.
[17]TAN MH，LI J，XU HE，et al.Androgen receptor：Structure，role in prostate cancer and drug discovery［J］.Acta Pharmacol Sin，2015，36(1)：3-23.
[18]PIETRI E，CONTEDUCA V，ANDREIS D，et al.Androgen receptor signaling pathways as a target for breast cancer treatment［J］.Endocr Relat Cancer，2016，23(10)：485-498.
[19]ANESTIS A，ZOI I，PAPAVASSILIOU AG，et al.Androgen receptor in breast cancer-clinical and preclinical research insights［J］.Molecules，2020，25(2)：358-368.
[20]VASILIOU SK，DIAMANDIS EP.Androgen receptor：A promising therapeutic target in breast cancer［J］.Crit Rev Clin Lab Sci，2019，56(3)：200-223.
[21]CHOI JE，KANG SH，LEE SJ，et al.Androgen receptor expression predicts decreased survival in early stage triple-negative breast Cancer［J］.Annals of Surgical Oncology，2015，22(1)：82-89.
[22]LIM E，NI M，CAO S，et al.Importance of breast cancer subtype in the development of androgen receptor directed therapy［J］.Curr Breast Cancer Rep，2014，6(2)：71-78.
[23]CHIA K，O' BRIEN M，BROWN M，et al.Targeting the androgen receptor in breast cancer［J］.Curr Oncol Rep，2015，17(2)：4-16.
[24]BASILE D，CINAUSERO M，IACONO D，et al.Androgen receptor in estrogen receptor positive breast cancer：Beyond expression［J］.Cancer Treatment Reviews，2017，61：15-22.
[25]LANZINO M，DE AMICIS F，MCPHAUL MJ，et al.Endogenous coactivator ARA70 interacts with estrogen receptor alpha(ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells［J］.J Biol Chem，2005，280(21)：20421-20430.
[26]DE AMICIS F，THIRUGNANSAMPANTHAN J，CUI Y，et al.Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells［J］.Breast Cancer Research and Treatment，2010，121(1)：1-11.
[27]CIUPEK A，RECHOUM Y，GU G，et al.Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer［J］.Breast Cancer Research and Treatment，2015，154(2)：225-237.
[28]COCHRANE DR，BERNALES S，JACOBSEN BM，et al.Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide［J］.Breast Cancer Research，2014，16(1)：7-25.
[29]CAO L，XIANG G，LIU F，et al.A high AR∶ERalpha or PDEF∶ERalpha ratio predicts a sub-optimal response to tamoxifen therapy in ERalpha-positive breast cancer［J］.Cancer Chemother Pharmacol，2019，84(3)：609-620.
[30]CREEVEY L，BLEACH R，MADDEN SF，et al.Altered steroid milieu in AI-resistant breast cancer facilitates AR mediated gene-expression associated with poor response to therapy［J］.Mol Cancer Ther，2019，18(10)：1731-1743.
[31]TAKAGI K，MIKI Y，NAGASAKI S，et al.Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment［J］.Endocrine-Related Cancer，2010，17(2)：415-430.
[32]HANAMURA T，NIWA T，NISHIKAWA S，et al.Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism［J］.Breast Cancer Research and Treatment，2013，139(3)：731-740.
[33]RECHOUM Y，ROVITO D，IACOPETTA D，et al.AR collaborates with ERα in aromatase inhibitor-resistant breast cancer［J］.Breast Cancer Research and Treatment，2014，147(3)：473-485.
[34]AMARAL C，AUGUSTO TV，ALMADA M，et al.The potential clinical benefit of targeting androgen receptor(AR) in estrogen-receptor positive breast cancer cells treated with exemestane［J］.Biochim Biophys Acta Mol Basis Dis，2020，1866(5)：165661-165673.
[35]I KROP VAMC.Results from a randomized placebo-controlled phase 2 trial evaluating exemestane±enzalutamide in patients with hormone receptor-positive breast cancer［J］.Cancer Research，2018，78(4)：4-7.
[36]ELEBRO K，BORGQUIST S，SIMONSSON M，et al.Combined androgen and estrogen receptor status in breast cancer：Treatment prediction and prognosis in a population-based prospective cohort［J］.Clinical Cancer Research，2015，21(16)：3640-3650.
[37]ALI A，CREEVEY L，HAO Y，et al.Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer［J］.Breast Cancer Research，2015，17(1)：123-141.
[38]KRABY MR，VALLA M，OPDAHL S，et al.The prognostic value of androgen receptors in breast cancer subtypes［J］.Breast Cancer Res Treat，2018，172(2)：283-296.
[39]VERA-BADILLO FE，TEMPLETON AJ，DE GOUVEIA P，et al.Androgen receptor expression and outcomes in early breast cancer：A systematic review and meta-analysis［J］.J Natl Cancer Inst，2014，106(1)：319-329.
[40]QU Q，MAO Y，FEI XC，et al.The impact of androgen receptor expression on breast cancer survival：A retrospective study and meta-analysis［J］.PLoS One，2013，8(12)：82650-82657.
[41]VENEMA CM，BENSE RD，STEENBRUGGEN TG，et al.Consideration of breast cancer subtype in targeting the androgen receptor［J］.Pharmacology & Therapeutics，2019，200：135-147.
[42]ELEBRO K，BORGQUIST S，SIMONSSON M，et al.Combined androgen and estrogen receptor status in breast cancer：Treatment prediction and prognosis in a population-based prospective cohort［J］.Clin Cancer Res，2015，21(16)：3640-3650.
[43]RANGEL N，RONDON-LAGOS M，ANNARATONE L，et al.The role of the AR/ER ratio in ER-positive breast cancer patients［J］.Endocr Relat Cancer，2018，25(3)：163-172.
[44]PARK S，PARK HS，KOO JS，et al.Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers［J］.Breast Cancer Research and Treatment，2012，133(1)：311-320.
[45]HIlBORN E，GACIC J，FORNANDER T，et al.Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer［J］.British Journal of Cancer，2016，114(3)：248-255.
[46]BRONTE G，ROCCA A，RAVAIOLI S，et al.Androgen receptor in advanced breast cancer：Is it useful to predict the efficacy of anti-estrogen therapy［J］.BMC Cancer，2018，18(1)：348-355.
[47]KENSLER KH，REGAN MM，HENG YJ，et al.Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer：Results from the Breast International Group Trial 1-98［J］.Breast Cancer Research，2019，21(1)：30-40.
[48]ACETO N，BARDIA A，WITTNER BS，et al.AR Expression in breast cancer CTCs associates with bone metastases［J］.Mol Cancer Res，2018，16(4)：720-727.
[49]DE LAERE B，VAN DAM PJ，WHITINGTON T，et al.Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns［J］.Eur Urol，2017，72(2)：192-200.
备注/Memo
- 备注/Memo:
- 广东省医学科学技术研究基金项目（编号：A2016441）
